Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
Qingli XiaoJin-Moo Lee

Abstract

In AD, an imbalance between Aβ production and removal drives elevated brain Aβ levels and eventual amyloid plaque deposition. APP undergoes nonamyloidogenic processing via α-cleavage at the plasma membrane, amyloidogenic β- and γ-cleavage within endosomes to generate Aβ, or lysosomal degradation in neurons. Considering multiple reports implicating impaired lysosome function as a driver of increased amyloidogenic processing of APP, we explored the efficacy of targeting transcription factor EB (TFEB), a master regulator of lysosomal pathways, to reduce Aβ levels. CMV promoter-driven TFEB, transduced via stereotactic hippocampal injections of adeno-associated virus particles in APP/PS1 mice, localized primarily to neuronal nuclei and upregulated lysosome biogenesis. This resulted in reduction of APP protein, the α and β C-terminal APP fragments (CTFs), and in the steady-state Aβ levels in the brain interstitial fluid. In aged mice, total Aβ levels and amyloid plaque load were selectively reduced in the TFEB-transduced hippocampi. TFEB transfection in N2a cells stably expressing APP695, stimulated lysosome biogenesis, reduced steady-state levels of APP and α- and β-CTFs, and attenuated Aβ generation by accelerating flux through the...Continue Reading

Citations

Mar 29, 2016·The Journal of Clinical Investigation·Keisuke KitakazeKohji Itoh
Sep 14, 2016·The Journal of Cell Biology·Chun-Yan Lim, Roberto Zoncu
Jun 15, 2016·Annual Review of Cell and Developmental Biology·Nina Raben, Rosa Puertollano
Dec 18, 2016·FEBS Letters·Andreas BeckUlrich Wissenbach
Dec 28, 2016·Journal of Neurochemistry·Lauren S WhyteTimothy J Sargeant
Jun 4, 2017·American Journal of Physiology. Heart and Circulatory Physiology·Xuejun Wang, Taixing Cui
Jun 3, 2016·Journal of Cell Science·Gennaro Napolitano, Andrea Ballabio
Apr 18, 2018·Annual Review of Neuroscience·Jaiprakash SharmaMarco Sardiello
Aug 18, 2018·Nature Reviews. Drug Discovery·Barry BolandMark J Millan
Aug 10, 2018·Journal of Neurochemistry·Lakshya BajajMarco Sardiello
Jun 27, 2018·Brain : a Journal of Neurology·Frances K WisemanUNKNOWN LonDownS Consortium
Aug 21, 2018·Brain : a Journal of Neurology·Song GaoVille-Petteri Mäkinen
Dec 5, 2019·Journal of Neuroscience Research·Dhruv PatelKalipada Pahan
Mar 4, 2017·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Alexis E GonzálezPatricia V Burgos
Aug 30, 2018·Cell Death & Disease·Gang ZhengXiaolei Zhang
Jan 27, 2019·Scientific Reports·Sijie TanEsther Wong
Jan 4, 2019·Nature Cell Biology·Rosalie E Lawrence, Roberto Zoncu
Jul 18, 2019·Frontiers in Cell and Developmental Biology·Chiara Di MaltaCarmine Settembre
Aug 20, 2019·Journal of Alzheimer's Disease : JAD·Sujyoti ChandraKalipada Pahan
Feb 6, 2020·Cells·Sandeep MalampatiAnd Min Li
Apr 25, 2018·Journal of Leukocyte Biology·Allison RahtesLiwu Li
Nov 30, 2018·Molecular Neurobiology·D OurdevSatyabrata Kar
Jun 12, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Wesley PengDimitri Krainc
Nov 27, 2019·Nature Reviews. Molecular Cell Biology·Andrea Ballabio, Juan S Bonifacino
Mar 28, 2018·Journal of Internal Medicine·R Loera-ValenciaP Nilsson
Nov 14, 2018·Oxidative Medicine and Cellular Longevity·Senthilkumar SivanesanJayakumar Rajadas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Alzheimer's Disease: Endosomes

Dysfunctional endosomal trafficking may be associated with Alzheimer’s disease (AD) pathology. Targeting the endosome may advance treatment options for AD. Here is the latest research on endosomes and AD.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.